Kierdorf H, Kindler J, Winterscheid R, Hollmann H J, Vorwerk D, Speck U
Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd. 1989;128:119-23.
The increasing life-expectancy of patients with end-stage renal failure has led to a significant increase of diagnostic and interventional radiologic measures. The contrast media used in these procedures, however, are excreted only very slowly, due to the renal failure. We have therefore studied the elimination of the nonionic x-ray contrast medium iopromide (Ultravist) during dialysis in nine anuric patients with end-stage renal failure. All of the patients received 100 ml iopromide (30 g iodine) for the visualization of their Cimino-Brescia shunt. They were then dialyzed 30 minutes after the injection. The plasma iodine concentration declined from 1.7 to 0.7 mg I/ml plasma during the 3-hour dialysis treatment. The iopromide clearance was a constant 80 ml/min. This is the equivalent of a relative dialysance of 65% of the creatinine clearance. There were no incidences of side effects requiring therapy in this high-risk group of patients. The quality of the image was good in all cases. Iopromide proved itself to be an x-ray contrast medium with a low rate of side effects, which can be effectively eliminated from the body by means of conventional dialysis.
终末期肾衰竭患者预期寿命的延长导致诊断性和介入性放射学检查显著增加。然而，由于肾衰竭，这些检查中使用的造影剂排泄非常缓慢。因此，我们研究了9例终末期肾衰竭无尿患者透析过程中对非离子型X线造影剂碘普罗胺（优维显）的清除情况。所有患者均接受100ml碘普罗胺（30g碘）以显影其西米诺-布雷西亚分流。注射后30分钟对他们进行透析。在3小时的透析治疗期间，血浆碘浓度从1.7mg I/ml血浆降至0.7mg I/ml血浆。碘普罗胺清除率恒定为80ml/min。这相当于肌酐清除率相对透析率的65%。在这个高危患者群体中没有出现需要治疗的副作用事件。所有病例的图像质量良好。碘普罗胺证明是一种副作用发生率低的X线造影剂，可通过常规透析有效地从体内清除。
